Immunovant takes on argenx, J&J with plans to test FcRn inhibitor in multiple parallel trials after PhI win
Immunovant is gearing up to start a slate of mid-stage as well as pivotal trials for its follow-on autoimmune drug, IMVT-1402, after confirming what it calls “best-in-class” potential in a Phase I healthy volunteer study.
Tuesday’s data update — on multiple ascending doses of 600 mg each — comes two months after news about the 300 mg cohort doubled Immunovant’s share price $IMVT and spurred a spike in the stock of Roivant $ROIV, which owns a controlling stake in Immunovant.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.